Beck Bode LLC’s Blueprint Medicines BPMC Stock Holding History

Beck Bode LLC’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-70	Closed	-$6K	–	111
2021 Q2	$6K	Buy	+70	New	+$6.41K	﹤0.01%	253

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Beck Bode LLC's BPMC Position: Q3 2021 in Review

Beck Bode LLC sold out of Blueprint Medicines (BPMC) in Q3 2021, closing a stake of 70 shares — an estimated $6K sold.

Beck Bode LLC first reported a position in BPMC in Q2 2021 and held it in 1 quarter. The position peaked at $6K in Q2 2021. 288 funds tracked by Wall St. Rank hold BPMC as of Q3 2021.

Beck Bode LLC reported no remaining Blueprint Medicines position as of Q3 2021 after selling out during the quarter.
Beck Bode LLC sold 70 Blueprint Medicines shares in Q3 2021, an estimated $6K.
Beck Bode LLC first reported a position in Blueprint Medicines in Q2 2021 and held it in 1 quarter.
Beck Bode LLC's Blueprint Medicines position peaked at $6K in Q2 2021.
288 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2021.

Based on Beck Bode LLC's 13F filing for Q3 2021, filed 22 Oct 2021.